Application of Multi-omics Analysis in Cancer Immunotherapy

Submission Deadline: 31 March 2026 View: 179 Submit to Special Issue

Guest Editors

Dr. Yutian Zou

Email: zouyt@sysucc.org.cn

Affiliation: Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, 651 East Dongfeng Road, Guangzhou, 510060, China.

Homepage:

Research Interests: Breast cancer; Immunotherapy; Tumor microenvironment; Anti-HER2 therapy; Drug resistance; Single-cell sequencing; CRISPR; CircRNA; Cell death; Ferroptosis; Organoid; Bioinformatics

Dr. Jindong Xie

Email: xiejd1@sysucc.org.cn

Affiliation: Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, 651 East Dongfeng Road, Guangzhou, 510060, China.

Homepage:

Research Interests: Oncology; Multi-omics; Tumor microenvironment; Immunotherapy

Dr. Shaoquan Zheng

Email: zhengshq3@mail2.sysu.edu.cn

Affiliation: Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, 651 East Dongfeng Road, Guangzhou, 510060, China.

Homepage:

Research Interests: Oncology; Multi-omics; Tumor microenvironment; Fibroblasts; Immunotherapy

Dr. Zui Pan

Email: zui.pan@uta.edu

Affiliation: College of Nursing and Health Innovation, The University of Texas at Arlington, Arlington, TX 76019, USA.

Homepage:

Research Interests: Physiology; Molecular biology; Cell biology; Tumor microenvironment

Dr. Zhi Tian

Email: ztian@usf.edu

Affiliation: College of Pharmacy, University of South Florida, Tampa, FL, USA.

Homepage:

Research Interests: Cell Biology; Cancer Research; Tumor microenvironment

Summary

According to statistics from the World Health Organization, cancer is recognized as the leading cause of mortality globally and persists as a significant challenge in the 21st century. Recently, immune checkpoint therapy has been validated as an effective approach for treating various advanced solid tumors and has rapidly become a focal point in antitumor drug research. Specifically, immune checkpoint therapy targeting programmed death ligand-1 (PD-L1) and programmed cell death protein-1 (PD-1) has demonstrated efficacy across multiple cancer types, resulting in notable improvements in both disease-free and overall survival rates among cancer patients. Nonetheless, certain cancers are characterized as immune-quiescent tumors, indicating that only a minority of patients derive benefit from immunotherapy, which is also associated with a high incidence of severe adverse events. The advancement of multi-omics analyses presents the potential for developing novel strategies to target factors within the tumor microenvironment, thereby enhancing the efficacy of cancer immunotherapy.

The scope encompasses a comprehensive examination of various facets of immunotherapies targeting the tumor microenvironment across diverse cancer types. This includes, but is not limited to, the development of novel strategies to augment the efficacy of immunotherapies, the mechanisms underlying immunotherapy resistance in cancer, the personalization of cancer immunotherapy, and the identification of biomarkers predictive of immunotherapy response. Additionally, it covers the application of bioinformatics and machine learning techniques for efficacy prediction, the role of non-coding RNAs in cancer immunotherapy, the implications of lipid metabolism, the function of exosomes, advancements in immunotherapeutic drug delivery systems, the mechanisms of immune escape in cancer, and the identification of novel immune cells or molecules within the cancer microenvironment.

We invite to this Special Issue the submission of scientific articles or reviews that focus on the application of multi-omics analyses in tumor immunotherapy.

Keywords

Published Papers